These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 18041348)
1. Thiazolidinediones and slowing the progression of diabetes. Jackson T; Aquilina A; Bloom J; Guerra-Garcia H; Salom I; Tzeel A; Kaminsky R Manag Care Interface; 2007 Aug; 20(8):29-34. PubMed ID: 18041348 [TBL] [Abstract][Full Text] [Related]
2. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime. Leier CV; Haas GJ J Am Coll Cardiol; 2007 Jul; 50(1):37-9. PubMed ID: 17601543 [No Abstract] [Full Text] [Related]
3. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes? Goldstein BJ Int J Clin Pract; 2006 Jul; 60(7):873-83. PubMed ID: 16846404 [TBL] [Abstract][Full Text] [Related]
4. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Leiter LA Diabet Med; 2005 Aug; 22(8):963-72. PubMed ID: 16026359 [TBL] [Abstract][Full Text] [Related]
5. Determinants of prescribing patterns for type II diabetes at Primary Care Trust level. Lloyd DC; Scrivener G J Clin Pharm Ther; 2004 Aug; 29(4):389-94. PubMed ID: 15271107 [TBL] [Abstract][Full Text] [Related]
6. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004. Patel H; Srishanmuganathan J; Car J; Majeed A J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257 [TBL] [Abstract][Full Text] [Related]
7. Suppression of post-prandial hyperglycaemia by pioglitazone improved islet fibrosis and macrophage migration in the Goto-Kakizaki rat. Mizukami H; Wada R; Yonezawa A; Sugawara A; Yagihashi S Diabetes Obes Metab; 2008 Sep; 10(9):791-4. PubMed ID: 18937646 [No Abstract] [Full Text] [Related]
8. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. Berger J Am J Manag Care; 2007 Apr; 13 Suppl 2():S55-8. PubMed ID: 17417934 [TBL] [Abstract][Full Text] [Related]
10. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Massi-Benedetti M; Orsini-Federici M Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473 [TBL] [Abstract][Full Text] [Related]
11. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360 [TBL] [Abstract][Full Text] [Related]
12. [Diabetes, heart, and glitazones]. Philippe J Rev Med Suisse Romande; 2004 Mar; 124(3):133-5. PubMed ID: 15095655 [No Abstract] [Full Text] [Related]
13. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282 [TBL] [Abstract][Full Text] [Related]
15. [Positioning of PROactive and its clinical application in Japan--a new direction in diabetes care discussed by diabetology and circulatory disease specialists: discussion]. Kawamori R; Kadowaki T; Daida H; Takeda N; Dormandy J Nihon Rinsho; 2006 Mar; 64(3):581-7. PubMed ID: 16732624 [No Abstract] [Full Text] [Related]
16. Management of type 2 diabetes mellitus with oral antihyperglycaemic therapy. Desai A; Tandon N Natl Med J India; 2007; 20(4):192-8. PubMed ID: 18085125 [No Abstract] [Full Text] [Related]
17. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. Hanyu H; Sato T; Kiuchi A; Sakurai H; Iwamoto T J Am Geriatr Soc; 2009 Jan; 57(1):177-9. PubMed ID: 19170800 [No Abstract] [Full Text] [Related]
18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Krentz A Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860 [TBL] [Abstract][Full Text] [Related]
19. Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes. Palmer AJ; Currie CJ Pharmacoeconomics; 2006; 24(9):927-9; author reply 929-35. PubMed ID: 16942126 [No Abstract] [Full Text] [Related]
20. [Prevention of type 2 diabetes mellitus: proven and new aspects]. Ritzel RA; Isermann B; Woerle HJ Dtsch Med Wochenschr; 2007 May; 132(19):1057-61. PubMed ID: 17476638 [No Abstract] [Full Text] [Related] [Next] [New Search]